Recent advances in ocular drug delivery
暂无分享,去创建一个
Kamel Alhanout | P. Piccerelle | V. Andrieu | K. Alhanout | Véronique Andrieu | Djamila Achouri | Philippe Piccerelle | Djamila Achouri | Kamel Alhanout
[1] L. Gan,et al. Novel microemulsion in situ electrolyte-triggered gelling system for ophthalmic delivery of lipophilic cyclosporine A: in vitro and in vivo results. , 2009, International journal of pharmaceutics.
[2] Rania M. Hathout,et al. Preparation and evaluation of reverse-phase evaporation and multilamellar niosomes as ophthalmic carriers of acetazolamide. , 2005, International journal of pharmaceutics.
[3] P. Sado,et al. Ophthalmic drug delivery systems—Recent advances , 1998, Progress in Retinal and Eye Research.
[4] A. Ludwig,et al. The use of mucoadhesive polymers in ocular drug delivery. , 2005, Advanced drug delivery reviews.
[5] Uday B Kompella,et al. Recent advances in ophthalmic drug delivery. , 2010, Therapeutic delivery.
[6] H. Tsuneoka,et al. Therapeutic effect of stealth-type polymeric nanoparticles with encapsulated betamethasone phosphate on experimental autoimmune uveoretinitis. , 2011, Investigative ophthalmology & visual science.
[7] P. J. Murphy,et al. Carbomer and Sodium Hyaluronate Eyedrops for Moderate Dry Eye Treatment , 2008, Optometry and vision science : official publication of the American Academy of Optometry.
[8] G. Spedalieri,et al. Flurbiprofen-loaded acrylate polymer nanosuspensions for ophthalmic application. , 2002, Biomaterials.
[9] M. Samaha,et al. Mucoadhesive liposomes as ocular delivery system: physical, microbiological, and in vivo assessment , 2009, Drug development and industrial pharmacy.
[10] Pushpa Mishra,et al. Sustained Ocular Drug Delivery from a Temperature and pH Triggered Novel In Situ Gel System , 2007, Drug delivery.
[11] D. Attwood,et al. In situ gelling xyloglucan formulations for sustained release ocular delivery of pilocarpine hydrochloride. , 2001, International journal of pharmaceutics.
[12] Y. Shimomura,et al. Reduction in intraocular pressure by the instillation of eye drops containing disulfiram included with 2-hydroxypropyl-β-cyclodextrin in rabbit. , 2010, Biological & pharmaceutical bulletin.
[13] S. Benita,et al. Ocular delivery of cyclosporin A. II. Effect of submicron emulsion's surface charge on ocular distribution of topical cyclosporin A , 2001 .
[14] A. Makky,et al. Mucoadhesive nanoparticles as carrier systems for prolonged ocular delivery of gatifloxacin/prednisolone bitherapy. , 2010, Molecular pharmaceutics.
[15] M. Aqil,et al. Evaluation of Carbopol-Methyl Cellulose Based Sustained-Release Ocular Delivery System for Pefloxacin Mesylate Using Rabbit Eye Model , 2006, Pharmaceutical development and technology.
[16] S. Benita,et al. Influence of Emulsion Droplet Surface Charge on Indomethacin Ocular Tissue Distribution , 2000, Pharmaceutical development and technology.
[17] G. Yener,et al. Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives , 2007, International journal of nanomedicine.
[18] H. Sasaki,et al. Different Effects of Absorption Promoters on Corneal and Conjunctival Penetration of Ophthalmic Beta-Blockers , 1995, Pharmaceutical Research.
[19] Siling Wang,et al. Topical use of coenzyme Q10-loaded liposomes coated with trimethyl chitosan: tolerance, precorneal retention and anti-cataract effect. , 2009, International journal of pharmaceutics.
[20] C. Sébastian,et al. A new long acting ophthalmic formulation of carteolol containing alginic acid. , 2000, International journal of pharmaceutics.
[21] P. Edman. Biopharmaceutics of Ocular Drug Delivery , 1992 .
[22] Robert Gurny,et al. PATENT LITERATURE REVIEW OF OPHTHALMIC INSERTS , 1995 .
[23] P. Maincent,et al. Poly(epsilon-caprolactone) nanocapsules in carteolol ophthalmic delivery. , 1993, Pharmaceutical research.
[24] D. Aggarwal,et al. Improved pharmacodynamics of timolol maleate from a mucoadhesive niosomal ophthalmic drug delivery system. , 2005, International journal of pharmaceutics.
[25] S. Seal,et al. Nanoceria particles prevent ROI-induced blindness. , 2008, Advances in experimental medicine and biology.
[26] P. Couvreur,et al. Cationic Vectors in Ocular Drug Delivery , 2004, Journal of drug targeting.
[27] Y. Lo,et al. Characterization of pilocarpine‐loaded chitosan/Carbopol nanoparticles , 2006, The Journal of pharmacy and pharmacology.
[28] M. Espina,et al. Flurbiprofen loaded biodegradable nanoparticles for ophtalmic administration. , 2006, Journal of pharmaceutical sciences.
[29] P. Maincent,et al. [Ways to improve ocular bioavailability for topical applications]. , 2000, Journal francais d'ophtalmologie.
[30] E. Stefánsson,et al. Topical and systemic absorption in delivery of dexamethasone to the anterior and posterior segments of the eye. , 2007, Acta ophthalmologica Scandinavica.
[31] R. Cavalli,et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. , 2002, International journal of pharmaceutics.
[32] A. El-Kamel,et al. Environmentally Responsive Ophthalmic Gel Formulation of Carteolol Hydrochloride , 2006, Drug delivery.
[33] John W. Shell. Ophthalmic drug delivery systems , 1984 .
[34] S. Jain,et al. Polymeric pseudolatices bearing pilocarpine for controlled ocular delivery. , 1992, Journal of microencapsulation.
[35] Weisan Pan,et al. Study of an alginate/HPMC-based in situ gelling ophthalmic delivery system for gatifloxacin. , 2006, International journal of pharmaceutics.
[36] F. Ahmad,et al. Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimisation and in vitro characterisation. , 2007, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.
[37] L. Laroche,et al. [Treatment of dry eye syndrome with lacrimal gel: a randomized multicenter study]. , 1991, Journal francais d'ophtalmologie.
[38] S. Saraf,et al. Cubosomes: an overview. , 2007, Biological & pharmaceutical bulletin.
[39] A. El-Kamel. In vitro and in vivo evaluation of Pluronic F127-based ocular delivery system for timolol maleate. , 2002, International journal of pharmaceutics.
[40] V. H. Lee,et al. Influence of Preparation Conditions on Acyclovir-Loaded Poly-d,l-Lactic Acid Nanospheres and Effect of PEG Coating on Ocular Drug Bioavailability , 2003, Pharmaceutical Research.
[41] J. Carlfors,et al. Rheological evaluation of Gelrite in situ gels for ophthalmic use. , 1998, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[42] M. Ghorab,et al. Nanosuspension as an ophthalmic delivery system for certain glucocorticoid drugs. , 2007, International journal of pharmaceutics.
[43] R. Gurny,et al. A water-soluble prodrug of cyclosporine A for ocular application: a stability study. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[44] P. J. Murphy,et al. Effectiveness of sodium hyaluronate eyedrops in the treatment of dry eye , 2005, Graefe's Archive for Clinical and Experimental Ophthalmology.
[45] I. Antal,et al. Gels and liposomes in optimized ocular drug delivery: studies on ciprofloxacin formulations. , 2007, International journal of pharmaceutics.
[46] Eaga Chandra Mohan,et al. Preparation and Evaluation of In-Situ-Gels for Ocular Drug Delivery , 2009 .
[47] A. Mahmoud,et al. Nanoemulsion as a Potential Ophthalmic Delivery System for Dorzolamide Hydrochloride , 2009, AAPS PharmSciTech.
[48] C. Allaire,et al. Ocular hypotensive efficacy and safety of once daily carteolol alginate , 2001, British Journal of Ophthalmology.
[49] S. P. Srinivas,et al. Use of fluorometry in assessing the efficacy of a cation-sensitive gel as an ophthalmic vehicle: comparison with scintigraphy. , 1992, Journal of pharmaceutical sciences.
[50] J W Shell,et al. Pharmacokinetics of topically applied ophthalmic drugs. , 1982, Survey of ophthalmology.
[51] F. Manvi,et al. In situ-forming hydrogels for sustained ophthalmic drug delivery. , 2007, Journal of controlled release : official journal of the Controlled Release Society.
[52] M. Alonso,et al. Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A. , 2001, International journal of pharmaceutics.
[53] L. Gan,et al. Novel vehicle based on cubosomes for ophthalmic delivery of flurbiprofen with low irritancy and high bioavailability , 2010, Acta Pharmacologica Sinica.
[54] K. Hosny. Preparation and Evaluation of Thermosensitive Liposomal Hydrogel for Enhanced Transcorneal Permeation of Ofloxacin , 2009, AAPS PharmSciTech.
[55] L. Gan,et al. Self-assembled liquid crystalline nanoparticles as a novel ophthalmic delivery system for dexamethasone: Improving preocular retention and ocular bioavailability. , 2010, International journal of pharmaceutics.
[56] Dina Fathalla,et al. Liposomes as an ocular delivery system of fluconazole: in‐vitro studies , 2010, Acta ophthalmologica.
[57] J. Romanet,et al. [Efficacy and safety of long-acting carteolol 1% once daily. A double-masked, randomized study]. , 2003, Journal francais d'ophtalmologie.
[58] J. C. Robinson. Ocular anatomy and physiology relevant to ocular drug delivery , 1993 .
[59] Siling Wang,et al. Freeze-dried liposomes as potential carriers for ocular administration of cytochrome c against selenite cataract formation. , 2009, The Journal of pharmacy and pharmacology.
[60] S. S. Imam,et al. Stimuli-sensitive hydrogels: A novel ophthalmic drug delivery system , 2010, Indian journal of ophthalmology.
[61] A. Mitra,et al. Corneal permeation of ganciclovir: mechanism of ganciclovir permeation enhancement by acyl ester prodrug design. , 2002, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[62] A. Vila,et al. Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. , 2006, Investigative ophthalmology & visual science.
[63] S. Fialho,et al. New vehicle based on a microemulsion for topical ocular administration of dexamethasone , 2004, Clinical & experimental ophthalmology.
[64] G. Abdelbary,et al. Niosome-Encapsulated Gentamicin for Ophthalmic Controlled Delivery , 2008, AAPS PharmSciTech.
[65] D. Aggarwal,et al. Role of cyclodextrins in ophthalmics. , 2004, Current drug delivery.
[66] D. Aggarwal,et al. Study of the extent of ocular absorption of acetazolamide from a developed niosomal formulation, by microdialysis sampling of aqueous humor. , 2007, International journal of pharmaceutics.
[67] Rania M. Hathout,et al. Liposomes as an ocular delivery system for acetazolamide: In vitro and in vivo studies , 2007, AAPS PharmSciTech.
[68] Philippe Maincent,et al. Moyens d'amélioration de la biodisponibilité pour la voie topique , 2000 .
[69] Jiasheng Tu,et al. Preparation and ocular pharmacokinetics of ganciclovir liposomes , 2007, The AAPS Journal.
[70] Indu Pal Kaur,et al. Ocular Preparations: The Formulation Approach , 2002, Drug development and industrial pharmacy.
[71] P. Amin,et al. Sustained ophthalmic delivery of ofloxacin from a pH triggered in situ gelling system. , 2001, Journal of controlled release : official journal of the Controlled Release Society.
[72] K. Hosny. Ciprofloxacin as Ocular Liposomal Hydrogel , 2010, AAPS PharmSciTech.
[73] D. Aggarwal,et al. Improved ocular absorption kinetics of timolol maleate loaded into a bioadhesive niosomal delivery system , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.
[74] D. Shastri,et al. Studies on In situ Hydrogel: A Smart Way for Safe and Sustained Ocular Drug Delivery , 2010, Journal of young pharmacists : JYP.
[75] Alejandro Sánchez,et al. Chitosan Nanoparticles as New Ocular Drug Delivery Systems: In Vitro Stability, in Vivo Fate, and Cellular Toxicity , 2005, Pharmaceutical Research.
[76] José Juan Escobar-Chávez,et al. Applications of thermo-reversible pluronic F-127 gels in pharmaceutical formulations. , 2006, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.
[77] E. Stefánsson,et al. Cyclodextrins in eye drop formulations: enhanced topical delivery of corticosteroids to the eye. , 2002, Acta ophthalmologica Scandinavica.
[78] Amélie Bochot,et al. Hyaluronic acid coated poly-epsilon-caprolactone nanospheres deliver high concentrations of cyclosporine A into the cornea. , 2008, Experimental eye research.
[79] S. Benita,et al. Evaluation of a positively charged submicron emulsion of piroxicam on the rabbit corneum healing process following alkali burn. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[80] J. Pandit,et al. Ion-Activated In Situ Gelling Systems for Sustained Ophthalmic Delivery of Ciprofloxacin Hydrochloride , 2003, Drug delivery.
[81] E. Stefánsson,et al. Comparison of topical 0.7% dexamethasone–cyclodextrin with 0.1% dexamethasone sodium phosphate for postcataract inflammation , 2006, Graefe's Archive for Clinical and Experimental Ophthalmology.
[82] B Pietzyk,et al. Degradation of phosphatidylcholine in liposomes containing carboplatin in dependence on composition and storage conditions. , 2000, International journal of pharmaceutics.
[83] W. Pan,et al. Preparation and Evaluation of Sustained Ophthalmic Gel of Enoxacin , 2005, Drug development and industrial pharmacy.
[84] A. A. Yasseen,et al. Nanoceria have no genotoxic effect on human lens epithelial cells , 2010, Nanotechnology.
[85] P. Maincent,et al. Poly(ε-Caprolactone) Nanocapsules in Carteolol Ophthalmic Delivery , 1993, Pharmaceutical Research.